

Publications

Anders Waage 22.05.2017

	1985
1	
2	
3	
4	
	1987
5	Waage A , Halstensen A, Espevik T. Tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. <i>Lancet</i> 1, 355-357, 1987.
6	Waage A . Production and clearance of tumor necrosis factor in rats exposed to endotoxin and dexamethasone. <i>Clin Immunol Immunopathol</i> 45, 348-355, 1987.
7	Waage A , Pedersen E, Petersen H, Martinussen M, Sandstrøm B, Isaksson B. Ernæringsstatus og kostinntak hos indremedisinske pasienter. <i>Tidsskr Nor Lægeforen</i> 107, 146-147, 1987.
8	Waage A , Naustdal T. Smoking and polycythaemia. <i>Lancet</i> ii, 1027, 1987 (letter).
9	Waage A , Naustdal T. Polycytemi og røyking. <i>Tidsskr Nor Lægeforen</i> 107, 354-355, 1987.
10	Evensen SA, Wisløff F, Muller E, Talstad I, Waage A , Johansen L. Aclarubicin in the treatment of relapsed or resistant acute myelogenous leukaemia: a phase II trial. <i>Scand J Haematol</i> 38, 43-47, 1987.
	1988
11	Waage A , Bakke O. Glucocorticoids suppress the production of tumour necrosis factor by lipopoly-saccharide-stimulated human monocytes. <i>Immunology</i> 63, 299-302, 1988.
12	Waage A , Espevik T. Interleukin 1 potentiates the lethal effect of tumor necrosis factor α /cachectin in mice. <i>J Exp Med</i> 167, 1987-1992, 1988.
13	Espevik T, Waage A . The involvement of tumor necrosis factor alpha (TNF- α) in immunomodulation and in septic shock. <i>Devel Biol Standard</i> 69, 139-142, 1988.
14	Waage A , Pedersen E, Petersen H, Martinussen M, Sandstrøm B, Isaksson B. Ernæringsstatus og kostinntak hos indremedisinske pasienter. <i>Tidsskriftskasett Nor Lægeforen</i> 1988.
15	Waage A , Austgulen R, Hofslie E, Lamvik J. Tumor-nekrose- faktor. <i>Tidsskr Nor Lægeforen</i> 108, 1786-1788, 1988.
16	Waage A , Espevik T, Halstensen A, Brandtzæg P, Kierulf P. Tumor nekrosefaktor. En mediator ved septisk sjokk. <i>Tidsskr Nor Lægeforen</i> 108, 1790-1792, 1988.
17	Waage A , Espevik T, Bakke O, Halstensen A, Brandtzaeg P, Kierulf P, Nissen-Meyer J, Lamvik J. Tumour necrosis factor in human septicaemia. In: <i>Tumor Necrosis Factor/Cachectin and Related Cytokines</i> . Bonavida, Gifford, Kirchner, Old, eds. Karger, Basel 1988, 148-53.
	1989
18	Waage A , Brandtzæg P, Halstensen A, Kierulf P, Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. <i>J Exp Med</i> 169, 333-338, 1989.
19	Waage A , Kaufmann C, Espevik T, Husby G. Interleukin-6 in synovial fluid from patients with arthritis. <i>Clin Immunol Immunopathol</i> 50, 394-398, 1989.
20	Waage A , Halstensen A, Shalaby R, Brandtzæg P, Kierulf P, Espevik T. Local production of tumor necrosis factor, interleukin 1 and interleukin 6 in meningococcal meningitis. Relation to the inflammatory response. <i>J Exp Med</i>

	170, 1859-1867, 1989.
21	Shalaby MR, Waage A , Espevik T. Cytokine regulation of interleukin 6 production by human endothelial cells. <i>Cell Immunol</i> 121, 372-382, 1989.
22	Shalaby MR, Waage A , Espevik T. Endotoxin, tumor necrosis factor- α /cachectin and interleukin 1 induce interleukin 6 production in vivo. <i>Clin Immunol Immunopathol</i> 53, 488-498, 1989.
	1990
23	Waage A , Størdal B, Sørensen M. Differential effect of oxpentifylline on tumour necrosis factor and interleukin 6 production. <i>Lancet</i> 335, i, 543, 1990 (letter).
24	Espevik T, Waage A , Faxvaag A, Shalaby R. Regulation of interleukin-2 and interleukin-6 production from T-cells: Involvement of interleukin-1b and transforming growth factor-b. <i>Cell Immunol</i> 126, 47-56, 1990.
25	Waage A , Slupphaug G, Shalaby R. Glucocorticoids inhibit the production of IL-6 from monocytes, endothelial cells and fibroblasts. <i>Eur J Immunol</i> 20, 2439-2443, 1990.
	1991
26	Liabakk N, Sundan A, Waage A , M Brockhaus, W Lesslauer, Espevik T. Development of immunoassays for the detection of soluble tumor necrosis factor receptors. <i>J Immunol Methods</i> 141, 237-43, 1991.
27	Shalaby MR, Halgunset J, Haugen OA, Aarset H, Aarden L, Waage A , Matsushima K, Kvithyll H, Boraschi D, Lamvik J, Espevik T. Cytokine-associated injury and lethality in mice: a comparative study. <i>Clin Immunol Immunopathol</i> 61, 69-82 1991.
	1992
28	Steinshamn S, Waage A . Production and role of tumor necrosis factor and interleukin 6 in candida albicans infection in normal and granulocytopenic mice. <i>Infect Immun</i> 60, 4003-8, 1992.
29	Waage A , Liabakk N, Espevik T. p55 and p75 TNF receptors in chronic lymphocytic leukemia. <i>Blood</i> 80, 2577-83, 1992.
30	Hofsli E, Waage A . Effect of pyridoxine on tumor necrosis factor activities in vitro. <i>Biotherapy</i> 5, 285-290, 1992.
31	Evensen S, Brinck L, Wisløff F, Talstad I, Waage A , Dahl IM. Oppfordring til ukritisk bruk av granulocyt-kolonistimulerende faktor (G-CSF) ? <i>Tidsskr Nor Lægeforen</i> . 112, 3122, 1992 (letter).
32	Brandtzæg P, Halstensen A, Kierulf P, Espevik T, Waage A . Molecular mechanisms in the compartmentalized inflammatory response presenting as meningococcal meningitis or shock. <i>Microbial Pathogenesis</i> 13, 423-431, 1992.
	1993
33	Halstensen A, Ceska P, Brandtzæg P, Redl H, Næss A, Waage A . Interleukin 8 in serum and cerebrospinal fluid in patients with meningococcal disease. <i>J Infect Dis</i> 167, 471-75, 1993.
34	Waage A , Halstensen A, Espevik T, Brandtzæg P. Compartmentalization of tumor necrosis factor, interleukin 1 and interleukin 6 to cerebrospinal fluid and serum in meningococcal disease. <i>Mediators Inflammation</i> 2, 23-25, 1993.
35	Almdahl S, Waage A , Ivert T, Vaage J. Release of bioactive interleukin 6 but not tumor necrosis factor alpha after elective cardiopulmonar bypass. <i>Perfusion</i> 8, 233-238, 1993.
36	Opsjøn S-L, Wathen NC, Tingulstad S, Wiedswang G, Sundan A, Waage A , Austgulen R. Tumor necrosis factor, Interleukin 1 and interleukin 6 in normal human pregnancy. <i>Am J Gynecol</i> , 169, 397-404, 1993.
37	Steinshamn S, Bergh K, Waage A . Effects of stem cell factor and granulocyte

	colony-stimulating factor on granulocyte recovery and candida albicans infection in granulocytopenic mice. J Infect Dis 168, 1444-8, 1993.
38	Børset M, Helset E, Naume B, Waage A . Lack of IL-1 production by myeloma cells purified with monodisperse magnetic beads. Br J Haematol 85, 446-451, 1993.
39	Waage A , Steinshamn S. Cytokine mediators in septic infections in the granulocytopenic and normal host. Eur J Haematol 50/5, 243-249, 1993.
	1994
40	Waage A , Remick D, Steinshamn S, LaForge M, Lamvik J. Interleukin 8 in serum in granulocytopenic patients with infection. Br J Haematol 86, 36-40, 1994.
41	Næss F, Waage A , Røise O, Stadaas JO, Aasen AO. Effects of a combined drug regimen on tumor necrosis factor and plasma kallekrein activity in experimental endotoxemia. Eur J Surg 160, 77-86, 1994.
42	Børset M, Waage A , OL Brekke, Helseth E. TNF and IL-6 are potent growth factors for OH-2, a novel human myeloma cell line. Eur J Haematol 53, 31-37, 1994.
43	Loraas A, Waage A , Lamvik J. Cytokine response pattern associated with myelodysplasia. Br J Haematol 87, 669-671, 1994.
44	Lamvik J, Dybedal I, Hammerstrøm J, Waage A . Acute leukemia middle Norway 1984-88. Leukemia Lymphoma 16, 65-71, 1994.
45	Williams KC, Ulvestad E, Waage A , Antel JP, McLaurin J. Activation of adult human derived microglia by myelin phagocytosis in vitro. J Neurosci Res 38, 433-43, 1994.
46	Lambertus JH van Tits, Bemelmans MHA, Steinshamn S, Waage A , Leeuwenberg JFM, Buurman, WA. Non signaling functions of TNF-R75: findings in man and mouse. Circ Shock 44, 40-44, 1994.
47	Brandtzæg P, Halstensen A, Kierulf P, Espevik T, Waage A . Molecular mechanisms in the compartmentalized inflammatory response presenting as meningococcal meningitis or shock. Microbial Pathogenesis 13, 423-431, 1992. Waage A . Monoklonalt antistoff mot endotoksin ved sepsis - markedsføring eller vitenskapelig vurdering ? Tidsskr Nor Lægefor 114, 951-953, 1994.
48	Waage A , Halstensen A, Espevik T, Brandtzæg P. Cytokine mediators in meningococcal disease. Bailliere Clinical Infectious Diseases. Griffin et al, eds. Bailliere Tindall, London, 97-108, 1994.
49	Waage A , Espevik T. Tumor necrosis factor receptors in chronic lymphocytic leukemia. Leukemia Lymphoma 13, 41-46, 1994.
	1995
50	Opsjøn SL, Austgulen R, Waage A . Interleukin 1, interleukin 6 and tumor necrosis factor at delivery in preeclamptic disorders. Acta Obstet Gynecol Scand 74, 19-26, 1995.
51	Steinshamn S, Bemelman M, Buurman WA, Waage A . Granulocytopenia reduces release of sTNFR-p75 in endotoxin stimulated mice: a possible mechanism of enhanced TNF activity. Cytokine 7, 50-56, 1995.
52	Steinshamn S, Brekke OL, Waage A . Soluble TNF receptors, tumor necrosis factor and interleukin 6 and in serum in granulocytopenia after chemotherapy. Br J Haematol, 89, 719-724, 1995.
53	Williams KC, Dooley NP, Ulvestad E, Waage A , Blain M, Yong VW, Antel JP. Antigen presentation by human fetal astrocytes: the cooperative effect of microglia or the microglial derived cytokine IL-1. J Neurosci 15; 1869-1878, 1995.
54	Sundan A, Ryan L, Brinch L, Espevik T, Waage A . Low CD 14 expression and

	impaired TNF secretion upon LPS stimulation in paroxysmal nocturnal hemoglobinuria restored after bone marrow transplantation. <i>Scand J Immunol</i> 41; 603-608, 1995.
55	Lehmann AK, Halstensen A, Sørnes S, Røkke O, Waage A . High levels of interleukin 10 is associated with case fatality in meningococcal disease. <i>Infect Immun</i> 63; 2109-2112, 1995.
56	Amundsen T, Waage A . Homocystein levels in patients with deep venous thrombosis. <i>Arteriosclerosis Res</i> 15; 1321-1323, 1995.
57	Hoffmann L Møller P, Pedersen-Bjergård J, Waage A , Pedersen M, Hirsch FR. Therapy-related acute promyelocyte leukemia with t(15;17)(q22;q12) following chemotherapy with drugs targeting DNA topoisomerase II. A report of two cases and a review of the literature. <i>Ann Oncol</i> 6; 781-788, 1995.
58	Børset M, Waage A , Sundan A. Hepatocyte growth factor reverses the TGF beta induced growth inhibition of CCL 64 cells: a novel bioassay for HGF and implications for the TGF beta bioassay. <i>J Immunol Methods</i> 189, 59-64, 1995.
59	Kossodo S, Houba V, Grau GE, the WHO collaborative study group (AW inkludert i denne gruppen). Assaying tumor necrosis factor concentrations in human serum. A WHO collaborative study. <i>J Immun Methods</i> 182, 107-114, 1995.
	1996
60	Linderholm M, Ahlm C, Settergren B, Waage A , Tarnvik A. Elevated plasma levels of TNF, IL-6 and IL-10 in patients with nephropathia epidemica, a hemorrhagic fever with renal syndrome. <i>J Infect Dis</i> 173, 38-43, 1996.
61	Hjertner Ø, Børset M, Waage A . Comparison of the effects of 2-chloroadenosine and melphalan on myeloma cell lines. <i>Leuk Lymphoma</i> 20, 155-160, 1996.
62	Steinshamn S, Bemelman M, Buurman WA, Waage A . Tumor necrosis factor receptors in <i>Candida albicans</i> infections: evidence for an important role of p55 in antifungal defence. <i>J Immunol</i> 157, 2155-2159, 1996.
63	Børset M, Lien E, Espevik T, Helseth E, Waage A , Sundan A. Concomitant expression of hepatocyte growth factor/scatter factor and its receptor c-met in human myeloma cell lines. <i>J Biol Chem</i> 271, 24655-24661, 1996.
64	Waage A Klinisk bruk av cytokiner og vekstfaktorer. <i>Tidsskr Nor Lægefor</i> 116, 2352, 1996. (letter)
65	Børset M, Hjort Hansen H, Seidel C, Sundan A, Waage A . Hepatocyte growth factor is associated with multiple myeloma. <i>Blood</i> , 88, 3998-4004, 1996.
66	Waage A , Halstensen A. The role of cytokines in the pathogenesis of meningococcal disease. <i>Current opinion Infect Dis</i> 9, 146-149, 1996
67	Waage A , Sundan A. Polycytemi på seierspallen. <i>Tidsskr Nor Lægefor</i> 116, 3695, 1996
68	Waage A , Dahl IM, Evensen S, Lamvik J, Sletnes K, Wisløff F. Klinisk bruk av cytokiner og vekstfaktorer. <i>Tidsskr Nor Lægefor</i> 116, 1465-1469, 1996
	1997
69	Abildgaard U, Brosstad F, Evensen S, Garberg K, Iversen OE, Nesheim B-J, Sandset PM, Sletnes K, Wisløff F, Waage A , Ødegaard OR. Vurdering av tromboasetendens før forskrivning av p-piller. <i>Tidsskr Nor Lægeforen</i> , 117, 281-282, 1997.
70	Waage A , Sundan A. Polycytemi på seierspallen. <i>Tidsskr Nor Lægefor</i> 117, 562, 1997 (korrespondanse)
71	Amundsen T, Kværness J, Jones RA, Waage A , Bjermer L, Nilsen G, Haraldseth O. MR perfusion imaging of patients with pulmonary embolism - a feasibility study. <i>Radiology</i> . 203, 181-185, 1997
72	Balteskard L, Unneberg K, Halvorsen D, Ytrebø LM, Waage A , Sjursen H,

	Revhaug A. The influence of growth hormone on tumor necrosis factor and neutrophil leukocyte function i sepsis. Scand J Infect Dis 29, 393-399, 1997
	1998
73	Waage, A. Tumour necrosis factor and septic shock. Lancet 351, 665, 1998 (letter).
74	Seidel C, Børset M, Turesson I, Abildgaard N, Sundan A, Waage A. Elevated serum concentrations of Hepatocyte growth factor in patients with multiple myeloma. Blood 91, 806,812, 1998
75	Carlsen SM, Waage A, Grill V, Følling I. Metformin increases circulating tumour necrosis factor- α levels in non-obese non-diabetic patients with coronary heart disease. Cytokine 10, 66-69, 1998
76	Seidel C, Børset M, Hjort-Hansen H, Sundan A, Waage A. Role of hepatocyte growth factor and its receptor c-met in multiple myeloma. Med Oncol 15, 145-153, 1998
	1999
77	Hjorth-Hanssen H, Seidel C, Lamvik J, Børset M, Sundan A, Waage A. Elevated serum concentrations of hepatoocyte growth factor in acute myeloid leukaemia. Eur J Hematol 62, 129-134, 1999
78	Hjorth-Hansen H, Seifert MF, Børset M, Aarset H, Østlie A, Sundan A, Waage A. Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice. J Bone Miner Res 14, 256-263, 1999
79	Børset M, Seidel C, Hjort-Hansen H, Waage A, Sundan A. The role of Hepatocyte growth factor and its receptor c-met in multiple myeloma and other blood malignancies. Leukemia Lymphoma, 32, 249-256, 1999
80	Hjorth-Hansen H, Waage A, Børset M. Interleukin-15 blocks apoptosis and induces proliferation of the human myeloma cell line OH-2 and freshly isolated myeloma cells. Br J Haematol 106,28-34,1999
81	Seidel C, Hjorth-Hansen H, Bendz B, Børset M, Sandset P-M, Hansen J-B, Sundan A, Waage A. Hepatocyte growth factor in serum after injection of unfractionated and low molecular weight heparin in healthy individuals. Br J Haematol 105, 641-647, 1999
82	Granert C, Raud J, Waage A, Lindquist L. Effects of the polysaccharide fucoidin on cerebrospinal fluid interleukin 1 and tumor necrosis alpha in pneumococcal meningitis in rabbits. Infect Immun. 67, 2071-2074, 1999.
83	Turesson I, Abildgaard N, Ahlgren T, Dahl I-M, Holmber E, Hjorth M, Nielsen JL, Oden A, Seidel C, Waage A, Westin J, Wisløff F for the Nordic Myeloma Study Group. Evaluation of prognostic factors in multiple myeloma. A multivariate analysis of presenting features in 394 patients. Br J Haematol. 106, 1005-12, 1999.
84	Hjertner Ø, Torgersen ML, Seidel C, Hjort-Hansen H, Waage A, Børset M, Sundan A. Hepatocyte growth factor induces interleukin 11 secretion from osteoblasts: A possible role for HGF in myeloma-associated osteolytic bone disease. Blood 94,3883-8,1999.
85	Børset M, Hjort-Hansen H, Johnsen A-C, Seidel C, Waage A, Espevik T, Sundan A. Apoptosis, proliferation and NF-kappaB activation induced by agonistic Fas-antibodies in the human myeloma cell line OH2; amplification of Fas-mediated apoptosis by tumor necrosis factor. Eur J Haematol 63, 345-53, 1999.

	2000
--	-------------

86	Seidel C, Sundan A, Hjort M, Turesson I, Dahl IM, Waage A , Børset M, for the Nordic Myeloma Study Group. Syndecan-1; a new independent prognostic marker in multiple myeloma. <i>Blood</i> 96,388-92,2000
87	Steinshamn S, Waage A . Lack of endotoxin tolerance with respect to TNF alpha production in the subarachnoid space. <i>APMIS</i> 108, 107-12, 2000.
88	Nordbø SA, Skaug K, Holter E, Waage A , Brinch L. Reactivation of hepatitis infection in an anti-HBc and anti-HBs positive patient after allogeneic transplantation. <i>Eur J Haematol</i> 65, 86-87, 2000.
89	Hjertner Ø, Qvigstad G, Hjort-Hansen H, Seidel C, Woodcliff J, Epstein J, Waage A , Sundan A, Børset M. Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells. <i>Br J Haematol</i> 109, 815-822, 2000.
90	Amundsen T, Torheim G, Waage A , Bjermer L, Steen PA, Haraldseth O. Perfusion magnetic resonance of the lung: Characterization of pneumonia and chronic obstructive pulmonary disease – a feasibility study. <i>JMRI</i> 12, 224-231, 2000.
91	Amundsen T, Kværness J, Aadahl P, Waage A , Bjermer L, Ødegård A, Haraldseth O. A closed chest pulmonary artery occlusion/reperfusion in the pig.: Detection of experimental pulmonary embolism with MR angiography and perfusion MR imaging. <i>Investigativ Radiol</i> 35, 295-303, 2000.
92	Ødegård A, Lundbom J, Myhre HO, Hatlinghus S, Bergh K, Waage A , Bjerve KS, Mollnes TE, Aadahl P, Lie TA, Videm V. The inflammatory response following treatment of abdominal aortic aneurysms: a comparison between open surgery and endovascular repair. <i>Eur J Endovasc Res</i> 19, 536-544, 2000
93	Seidel C, Børset M, Hjertner Ø, Cao D, Abildgaard N, Hjort-Hansen H, Sanderson RD, Waage A , Sundan A. High levels of soluble syndecan-1 in myeloma-derived bone marrow; modulation of HGF activity. <i>Blood</i> 96, 3139-3146, 2000.
	2001
94	Hjertner Ø, Hjort-Hansen H (equal contribution), Børset M, Seidel C, Waage A , Sundan A. Bone morphogenetic protein-4 induces apoptosis of multiple myeloma cells. <i>Blood</i> 97, 516-522, 2001.
95	Græsdal JS, Gundersen K, Holm B, Waage A . Thalassemi og sigdcellesykdom i Norge. <i>Tidsskr Nor Laegefor</i> 121, 678-680, 2001
96	Seidel C, Hjertner Ø (equal contribution), Abildgaard N, Heickendorff L, Hjorth M, Westin J, Lanng Nielsen J, Hjort-Hansen H, Waage A , Sundan A, Børset M. The Nordic Myeloma Study Group. Serum osteoprotegerin (OPG) levels are reduced in multiple myeloma patients with lytic bone disease. <i>Blood</i> 98, 2269-71, 2001
97	Wisløff F, Tangen JM, Brinch L, Dahl IM, Gruber FX, Hammerstrøm J, Waage A , Nesthus I, Ernst P. Høydosebehandling med autolog stamcellestøtte – endelig et fremskritt i behandlingen av myelomatose. <i>Tidsskr Nor Laegefor</i> 121,678-80, 2001
98	Liabakk NB, Waage A , Lien E, Stenvik J, Espevik T. Methods in Molecular Medicine. <i>Cytokine Bioassays</i> 67 , 2001
99	Waage A , Seidel C. Thalidomid – gammelt medikament med nye bruksområder. <i>Tidsskr Nor Laegefor</i> 121,678-80, 2001
	2002
100	Dybdahl B, Wahba A, Lien E, Flo TH, Waage A , Qureshi N, Sellevold OFM, Espevik T, Sundan A. Inflammatory response after open heart surgery. Release of heat-shock protein 70 and signaling through toll-like receptor-4. <i>Circulation</i> 105, 685-90, 2002.
101	Amundsen T, Torheim G, Kvistad KA, Waage A , Bjermer L, Nordlid KK, Johnsen H,

	Åsberg A, Haraldseth O. Perfusion abnormalities in pulmonary embolism studied with perfusion MRI and ventilation-perfusion scintigraphy: An intra-modality and inter-modality agreement study. <i>J Magnetic Resonance Imaging</i> . 15, 386-94, 2002.
102	Brenne AT, Baade Ro T, Waage A , Sundan A, Borset M, Hjorth-Hansen H. Interleukin-21 is a growth and survival factor for human myeloma cells. <i>Blood</i> . 99,3756-62, 2002.
103	Standal T, Seidel C, Hjertner Ø, Plesner T, Sanderson RD, Waage A , Borset M, Sundan A. Osteoprotegerin is bound, internalized and degraded by multiple myeloma cells. <i>Blood</i> 100,3002-3007, 2002.
104	Standal T, Borset M, Lenhoff S, Wisloff F, Størdal B, Sundan, A, Waage A , Seidel C. Serum insulin-like growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor. <i>Blood</i> 100, 3925-3929, 2002
105	Stovner LJ, Hagen K, Waage A , Bjerve KS. Hereditary haemochromatosis in two cousins with cluster headache. <i>Cephalgia</i> 22, 317-9,2002
106	Seidel C, Lenhoff S, Brabrand S, Anderson G, Standal T, Lanng-Nielsen J, Turesson I, Børset M, Waage A . Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapy. <i>Br J Haematol</i> 119, 672-676, 2002
107	Dybdahl B, Wahba A, Lien E, Flo TH, Waage A , Qureshi N, Sellevold OFM, Espevik T, Sundan A. Heat shock proteins and endotoxin combined as a trigger for inflammatory cytokine release during cardiopulmonary bypass: a possible third way ? <i>Circulation</i> 106, 49-50, 2002 (letter).
	2003westin
108	Erikson T, HøglundP, Turesson I, Waage A , Don BR, Wu J, Kaysen GA. Pharmacokinetics of thalidomide during dialysis and in patients with impaired renal function. <i>J Pharm Pharmacol</i> 55,1701-6, 2003.
	2004
109	Standal T, Hjorth Hansen H, Rasmussen T, Dahl IM, Lenhoff S, Brenne AT, Seidel C, Baykov V, Waage A , Borset M, Sundan A, Hjertner Ø. Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma. <i>Haematologica</i> 89,174-82, 2004
110	Waage A , Turesson I, Juliusson G, Gimsing P, Gulbrandsen N, Wisløff F Eriksson T, Lanng-Nielsen J, Westin J, Lenhoff S, Hjorth M. The Nordic Myeloma Study Group. Early response predicts thalidomide efficiency in patients with advance multiple myeloma. <i>Br J Haematol</i> 125, 149-55, 2004
111	Bade Rø T, Utne Holt R, Brenne AT, Hjorth Hansen H, Waage A , Hjertner Ø, Sundan A, Børset M. Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells. <i>Oncogene</i> 23, 3024-32, 2004.
112	Hov H, Holt RU, Ro TB, Fagerli UM, Hjorth-Hansen H, Baykov V, Christensen JG, Waage A , Sundan A, Borset M. A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells. <i>Clin Cancer Res</i> . 10,6686-94, 2004.
113	Brenne AT, Romstad LH, Gimsing P, Juliusson G, Turesson I, Borset M, Sundan A, Waage A . A low serum level of soluble tumor necrosis factor receptor p55 predicts for response to thalidomide in advanced myeloma. <i>Haematologica</i> .89, 552-6, 2004.

	2005
--	------

114	Holt RU, Baykov V, Ro TB, Brabrand S, Waage A, Sundan A, Børset M. Human myeloma cells adhere to fibronectin in response to hepatocyte growth factor. <i>Haematologica</i> . ;90(4):479-88, 2005.
115	Dybdahl B, Slordahl SA, Waage A , Kierulf P, Espevik T, Sundan A. Myocardial ischaemia and the inflammatory response: release of heat shock protein 70 after myocardial infarction. <i>Heart</i> . 91:299-304, 2005
116	Hjertner O, Standal T, Børset M, Sundan A, Waage A . Identification of new targets for therapy of osteolytic bone disease in multiple myeloma. <i>Current Drug Targets</i> 6:701-11. 2005.
	2006
117	Hjertner, Ø; Standal, T, Børset, M, Sundan, A, Waage, A . Bone disease in multiple myeloma. <i>Medical Oncology</i> 23:431-441, 2006
	2007
118	Waage, A . Om hundre år er allting kjent. <i>Tidsskr Nor Laegeforen</i> . 127:2680, 2007
119	Lamvik, J, Waage, A , Freim Wahl, S, Næss, IA, Quist Paulsen, P, Hammerstrøm, J.. Adult acute lymphoblastic leukemia, Burkitt's lymphoma and lymphoblastic lymphoma in middle Norway 1985-2004. <i>Haematologica</i> 2006;01:1428-1429
	2008
120	Fagerli UM, Holt RU, Holien T, Vaatsveen TK, Zhan F, Egeberg KW, Barlogie B, Waage A , Aarset H, Dai HY, Shaughnessy JD Jr, Sundan A, Børset M. Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells. <i>Blood</i> .111:806-15, 2008
121	Holt RU, Fagerli UM, Baykov V, Rø TB, Hov H, Waage A , Sundan A, Børset M. Hepatocyte growth factor promotes migration of human myeloma cells. <i>Haematologica</i> 93:619-22, 2008
122	Wader K, Fagerli U, Holt R, Stordal B, Børset M, Sundan A, Waage A . Elevated Serum Concentrations of Activated Hepatocyte Growth Factor Activator in Patients with Multiple Myeloma. <i>Eur J Haematol</i> . 81, 380-3, 2008.
123	Slørdahl TS, Hov H, Holt RU, Baykov V, Syversen T, Sundan A, Waage A , Børset M. Mn ²⁺ regulates myeloma cell adhesion differently than the proadhesive cytokines HGF, IGF-1, and SDF-1alpha. <i>Eur J Haematol</i> . 8, 1437-47, 2008.
124	Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D, Bladé J, Kyle R, Westin J, Weber D, Bringhen S, Niesvizky R, Waage A , von Lilienfeld-Toal M, Lonial S, Morgan GJ, Orłowski RZ, Shimizu K, Anderson KC, Boccadoro M, Durie BG, Sonneveld P, Hussein MA; International Myeloma Working Group. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. <i>Leukemia</i> 22:414-23, 2008
125	Palumbo A, Facon T, Sonneveld P, Bladé J, Offidani M, Gay F, Moreau P, Waage A , Spencer A, Ludwig H, Boccadoro M, Harousseau JL. Thalidomide for treatment of multiple myeloma: 10 years later. <i>Blood</i> 111:3968-77, 2008
126	Børset M, Standal T, Waage A , Sundan A. Hepatocyte growth factor in the pathogenesis of multiple myeloma. <i>Cellular Ther Transplant</i> . 1:57-60, 2008
	2009
127	Hov H, Tian E, Holien T, Holt RU, Våtsveen TK, Fagerli UM, Waage A , Børset M, Sundan A. c-Met signaling promotes IL-6-induced myeloma cell proliferation. <i>Eur J Haematol</i> . 82, 277-87, 2009.
128	Brenne AT, Fagerli UM, Shaughnessy JD Jr, Våtsveen TK, Rø TB, Hella H, Zhan F, Barlogie B, Sundan A, Børset M, Waage A . High expression of BCL3 in human

	myeloma cells is associated with increased proliferation and inferior prognosis. Eur J Haematol. 82, 354-63, 2009.
129	Reseland JE, Reppe S, Olstad OK, Hjorth-Hansen H, Brenne AT, Syversen U, Waage A , Iversen PO. Abnormal adipokine levels and leptin-induced changes in gene expression profiles in multiple myeloma. Eur J Haematol 83, 460-70, 2009.
130	Våtsveen TK, Brenne AT, Dai HY, Waage A , Sundan A, Børset M. FGFR3 is expressed and is important for survival in INA-6, a human myeloma cell line without a t(4;14). Eur J Haematol. 83, 471-6, 2009.
131	Terpos E, Sezer O, Croucher PI, García-Sanz R, Boccadoro M, San Miguel J, Ashcroft J, Bladé J, Cavo M, Delforge M, Dimopoulos MA, Facon T, Macro M, Waage A , Sonneveld P. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 20, 1303-17, 2009 .
132	Bird J, Behrens J, Westin J, Turesson I, Drayson M, Beetham R, D'Sa S, Soutar R, Waage A , Gulbrandsen N, Gregersen H, Low E; Haemato-oncology Task Force of the British Committee for Standards in Haematology, UK Myeloma Forum and Nordic Myeloma Study Group. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol. 147,22-42, 2009.
	2010
133	Waage A, Gimsing P, Fayers P, Abildgaard N, Ahlberg L, Björkstrand B, Carlson K, Dahl IM, Forsberg K, Gulbrandsen N, Haukås E, Hjertner Ø, Hjorth M, Karlsson T, Knudsen L, Nielsen JL, Linder O, Mellqvist UH, Nesthus I, Rolke J, Strandberg M, Sørnbø JH, Wisløff F, Juliusson G, Turesson I, for the Nordic Myeloma Study Group. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood 116:1405-12,2010..
134	Gimsing P, Carlson K, Turesson I, Fayers P, Waage A , Vangsted A, Mylin A, Gluud C, Juliusson G, Gregersen H, Hjorth-Hansen H, Nesthus I, Dahl IM, Westin J, Nielsen JL, Knudsen LM, Ahlberg L, Hjorth M, Abildgaard N, Andersen NF, Linder O, Wisløff F. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. Lancet Oncol. 11:973-82,2010.
135	European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma. Engelhardt M, Udi J, Kleber M, Spencer A, Rocci A, Knop S, Bruno B, Bringhen S, Pérez-Simón JA, Zweegman S, Driessen C, Patriarca F, Gramatzki M, Terpos E, Sezer O, Kropff M, Straka C, Johnsen HE, Waage A , Boegsted M, Lokhorst H, Hájek R, Morgan G, Boccadoro M, Ludwig H, Cavo M, Polliack A, Sonneveld P, Einsele H, Palumbo A. Leuk Lymphoma 51:2006-11: 2010.
	2011
136	Wader K, Fagerli U, Holt R, Børset M, Sundan A, Waage A . Soluble c-Met in serum of multiple myeloma patients: correlation with clinical parameters. Eur J Haematol. 87:394-9,2011.
137	Fayers PM, Palumbo A, Hulin C, Waage A , Wijermans P, Beksaç M, Bringhen S, Mary JY, Gimsing P, Termorshuizen F, Haznedar R, Caravita T, Moreau P, Turesson I, Musto P, Benboubker L, Schaafsma M, Sonneveld P, Facon T.

	Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from six randomized clinical trials. <i>Blood</i> 118:1239-47; 2011.
138	Mellstedt H, Gimsing P, Waage A . Treatment of myeloma when high dose therapy is not possible. New drugs--alternatives for elderly patients. <i>Lakartidningen</i> 108:2090-4; 2011. PMID 22165535
	2012
139	Holien T, Våtsveen TK, Hella H, Rampa C, Brede G, Grøseth LA, Rekvig M, Børset M, Standal T, Waage A , Sundan A. Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC. <i>Leukemia</i> 5:1073-80; 2012.
140	Wader KF, Fagerli UM, Børset M, Lydersen S, Hov H, Sundan A, Bofin A, Waage A . Immunohistochemical analysis of hepatocyte growth factor and c-Met in plasma cell disease. <i>Histopathology</i> 60:443-51; 2012. PMID 22276607
141	Holien T, Våtsveen TK, Hella H, Waage A , Sundan A. Addiction to c-MYC in multiple myeloma. <i>Blood</i> 120:2450-3; 2012. PMID 22806891
142	Ludwig H, Durie BG, McCarthy P, Palumbo A, San Miguel J, Barlogie B, Morgan G, Sonneveld P, Spencer A, Andersen KC, Facon T, Stewart KA, Einsele H, Mateos MV, Wijermans P, Waage A , Beksac M, Richardson PG, Hulin C, Niesvizky R, Lokhorst H, Landgren O, Bergsagel PL, Orłowski R, Hinke A, Cavo M, Attal M; International Myeloma Working Group. IMWG consensus on maintenance therapy in multiple myeloma. <i>Blood</i> 9;119:3003-15;2012 Review. PMID 22271445
143	Morgan G, Johnsen HE, Goldschmidt H, Palumbo A, Cavo M, Sonneveld P, Miguel JS, Chim C, Browne P, Einsele H, Waage A , Turesson I, Spencer A, Hajek R, Ludwig H, Hemminki K, Houlston R. MAGIC (Myeloma Genetics International Consortium) <i>Leuk Lymphoma</i> 53:796-800; 2012. PMID 22080755
	2013
144	Palumbo A, Waage A , Hulin C, Beksac M, Zweegman S, Gay F, Gimsing P, Leleu X, Wijermans P, Sucak G, Pezzatti S, Juliusson G, Pégourié B, Schaafsma M, Galli M, Turesson I, Kolb B, van der Holt B, Baldi I, Rolke J, Ciccone G, Wetterwald M, Lokhorst H, Boccadoro M, Rodon P, Sonneveld P. Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. <i>Haematologica</i> . 98:87-94; 2013. PMID 22875621
145	Misund K, Baranowska K, Holien T, Rampa C, Klein D, Børset M, Waage A , Sundan A. A method for measurement of drug sensitivity of myeloma cells co-cultured with bone marrow stromal cells. <i>J Biomed Scr</i> , 18:637-46;2013
146	Holien T, Olsen OE, Misund K, Hella H, Waage A , Rø TB, Sundan A. Lymphoma and myeloma cells are highly sensitive to growth arrest and apoptosis induced by artesunate. <i>Eur J Haematol</i> . 91:339-46;2013.
147	HGF and IGF-1 synergize with SDF-1 α in promoting migration of myeloma cells by cooperative activation of p21-activated kinase. Rø TB, Holien T, Fagerli UM, Hov H, Misund K, Waage A , Sundan A, Holt RU, Børset M. <i>Exp Hematol</i> . 2013;41:646-55. PMID 23499762

148	Mellqvist UH, Gimsing P, Hjertner Ø, Lenhoff S, Laane E, Remes K, Steingrimsdottir H, Abildgaard N, Ahlberg L, Blimark C, Dahl IM, Forsberg K, Gedde-Dahl T, Gregersen H ³ , Gruber A, Guldbrandsen N, Haukås E, Karlson C, Kvam AK, Linder O, Nahi H, Lindås R, Toffner-Clausen NA, Silvennoinen R, Andersen NF, Turesson I, Waage A , MD ³ and Westin J for the Nordic Myeloma Study Group. Bortezomib consolidation after autologous stem cell transplantation; a Nordic Myeloma Study Group randomized phase III trial. <i>Blood</i> 121:4647-54;2013. PMID 23616624
	2014
149	Morabito F, Brinthen S, Larocca A, Wijermans P, Victoria Mateos M, Gimsing P, Mazzone C, Gottardi D, Omedè P, Zweegman S, José Lahuerta J, Zambello R, Musto P, Magarotto V, Schaafsma M, Oriol A, Juliusson G, Cerrato C, Catalano L, Gentile M, Isabel Turel A, Marina Liberati A, Cavalli M, Rossi D, Passera R, Rosso S, Beksac M, Cavo M, Waage A , San Miguel J, Boccadoro M, Sonneveld P, Palumbo A, Offidani M. Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study. <i>Am J Hematol</i> ;89:355-62;2014. PMID:24273190
150	van de Donk NW, Palumbo A, Johnsen HE, Engelhardt M, Gay F, Gregersen H, Hajek R, Kleber M, Ludwig H, Morgan G, Musto P, Plesner T, Sezer O, Terpos E, Waage A , Zweegman S, Einsele H, Sonneveld P, Lokhorst HM. The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. <i>Haematologica</i> . 99:984-96;2014. PMID:24658815
151	von Krogh AS, Kremer Hovinga JA, Tjønnfjord GE, Ringen IM, Lämmle B, Waage A , Quist-Paulsen P. The impact of congenital thrombotic thrombocytopenic purpura on pregnancy complications. <i>Thromb Haemost</i> . 2014 Feb 6;111(6). PMID:24499950
152	Palumbo A, Brinthen S, Kumar SK, Lupparelli G, Usmani S, Waage A , Larocca A, van der Holt B, Musto P, Offidani M, Petrucci MT, Evangelista A, Zweegman S, Nooka AK, Spencer A, Dimopoulos MA, Hajek R, Cavo M, Richardson P, Lonial S, Ciccone G, Boccadoro M, Anderson K, Barlogie B, Sonneveld P, McCarthy PL. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. <i>Lancet Oncol</i> . 15:333-42;2014. PMID:24525202
153	Olsen OE, Wader KF, Misund K, Våtsveen TK, Rø TB, Mylin AK, Turesson I, Størdal BF, Moen SH, Standal T, Waage A , Sundan A, Holien T. Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin. <i>Blood Cancer J</i> . 2014;. 4:e196. PMID:24658374
154	Rampa C, Tian E, Våtsveen TK, Buene G, Slørdahl TS, Børset M, Waage A , Sundan A. Identification of the source of elevated hepatocyte growth factor levels in multiple myeloma patients. <i>Biomark Res</i> . April 9;2:8;2014. PMID:24716444
	2015
155	Blix ES, Kildal AB, Bertelsen E, Waage A , Myklebust JH, Kolstad A, Husebekk A. Content of Endothelial Progenitor Cells in Autologous Stem Cell Grafts Predict Survival after Transplantation for Multiple Myeloma.

	Biol Blood Marrow Transplant. 2015 Feb 14. pii: S1083-8791(14)01471-2. doi: 10.1016/j.bbmt.2014.12.027.PMID: 25689789
156	Ghanima W, Khelif A, Waage A , Michel M, Tjønnfjord GE, Romdhan NB, Kahrs J, Darne B, Holme PA; on behalf of the RITP study group. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015 Feb 4. pii: S0140-6736(14)61495-1. doi: 10.1016/S0140-6736(14)61495-1. PMID: 25662413
157	Even Rustad , Hong Yan Dai, Håkon Hov, Eivind Coward, Vidar Beisvåg, Ola Myklebost, Eivind Hovig, Sigve Nakken, Daniel Vodák, Leonardo Meza-Zepeda, Arne Sandvik, Karin Wader, Kristine Misund, Anders Sundan, Harald Aarset, Waage A , BRAF. V600E mutation in early stage multiple myeloma; good response to broad acting drugs and no relation to prognosis. Blood Cancer Journal, Mar 20;5:e299. doi: 10.1038/bcj.2015.24, 2015 PMID 25794135
158	Nahi H, Våtsveen TK, Lund J, Heeg BM, Preiss B, Alici E, Møller MB, Wader KF, Møller HE, Grøseth LA, Østergaard B, Dai HY, Holmberg E, Gahrton G, Waage A (equal contribution), Abildgaard N (equal contribution). Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21. Eur J Haematol. 2015;96(1):46-54. PMID 25779478
159	Grövdal M, Nahi H, Gahrton G, Liwing J, Waage A , Abildgaard N, Pedersen PT, Hammerstrøm J, Laaksonen A, Bazia P, Terava V, Ollikainen H, Silvennoinen R, Putkonen M, Anttila P, Porkka K, Remes K. Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT. Bone Marrow Transplant. 2015 50(6):808-12. PMID PMID 25867654
160	Beksac M, Waage A , Bringham S, Kristinsson SY, Sucak GT, Gimsing P, Lupporelli G, Firatlı-Tuğlular T, Juliusson G, Turesson I, Palumbo A. Does Low-Molecular-Weight Heparin Influence the Antimyeloma Effects of Thalidomide? A Retrospective Analysis of Data from the GIMEMA, Nordic and Turkish Myeloma Study Groups. Acta Haematol. 2015 Mar 24;133(4):372-380. PMID:25824293
161	Swaminathan B, Thorleifsson G, Jöud M, Ali M, Johnsson E, Ajore R, Sulem P, Halvarsson B-M, Eyjolfsson G, Haraldsdottir V, Hultman C, Ingelsson E, Kristinsson S, Kahler A, Lenhoff S, Masson G, Mellqvist U-H, Månsson R, Nelander S, Olafsson I, Sigurdardottir O, Steingrimsdottir H, Vangsted A, Vogel U, Waage A , Nahi H, Gudbjartsson D, Rafnar T, Turesson I, Gullberg U, Stefansson K, Hansson, M, Thorsteinsdottir U, and Nilsson B. Variants in <i>ELL2</i> influencing immunoglobulin levels associate with multiple myeloma. Nature Com 6:7213;2015. PMID:26007630
162	Kvam AK, Waage A . Health-related quality of life in patients with multiple myeloma - does it matter? Invited editorial. Haematologica 100: 704-705; 2015 PMID:26034111
163	Sponaas AM, Moen SH, Liabakk NB, Feyzi E, Holien T, Kvam S, Grøseth LA, Størdal B, Buene G, Espevik T, Waage A , Standal T, Sundan A. The proportion of CD16(+)CD14(dim) monocytes increases with tumor cell load in bone marrow of patients with multiple myeloma. Immun Inflamm Dis. 2:94-102;2015.PMID 26029369
164	Olsen OE, Wader KF, Hella H, Mylin AK, Turesson I, Nesthus I, Waage A , Sundan A, Holien T. Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B.

	Cell Commun Signal. 13:27;2015. PMID 6047946
165	Westhrin M, Moen SH, Holien T, Mylin AK, Heickendorff L, Olsen OE, Sundan A, Turesson I, Gimsing P, Waage A , Standal T. GDF15 promotes osteoclast differentiation, inhibits osteoblast differentiation and high serum GDF15 levels are associated with multiple myeloma bone disease. Haematologica. 2015 Aug 20. pii: haematol.2015.124511. PMID 26294726
166	Tian E, Børset M, Sawyer JR, Brede G, Våtsveen TK, Hov H, Waage A , Barlogie B, Shaughnessy JD Jr, Epstein J, Sundan A. Allelic mutations in noncoding genomic sequences construct novel transcription factor binding sites that promote gene overexpression. Genes Chromosomes Cancer. 2015 Nov;54(11):692-701. PMID:26220195
167	von Krogh AS, Kremer Hovinga JA, Romundstad PR, Roten LT, Lämmle B, Waage A , Quist-Paulsen P. ADAMTS13 gene variants and function in women with preeclampsia: A population- based nested case- control study from the HUNT Study. Thromb Res. 2015 Aug;136(2):282-8. PMID:26139087
168	Holien T, Misund K, Olsen OE, Baranowska KA, Buene G, Børset M, Waage A , Sundan A. MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy. Oncotarget. 2015;6:22698-705. PMID 26087190
169	PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy. Sponaas AM, Moharrami NN, Feyzi E, Standal T, Holth Rustad E, Waage A , Sundan A. PLoS One. 2015 Oct 7;10(10):e0139867. doi:0.1371/journal.pone.0139867. 2015. PMID 26444869
	2016
170	High prevalence of hereditary thrombotic thrombocytopenic purpura in Central Norway: from clinical observation to evidence. von Krogh AS, Quist-Paulsen P, Waage A, Langseth ØO, Thorstensen K, Brudevold R, Tjønnfjord GE, Largiadèr CR, Lämmle B, Kremer Hovinga JA. J Thromb Haemost. 1:73-82;2016. PMID:26566785
171	Zweegman S, van der Holt B, Mellqvist UH, Salomo M, Bos GM, Levin MD, Visser-Wisselaar H, Hansson M, van der Velden AW, Deenik W, Gruber A, Coenen JL, Plesner T, Klein SK, Tanis BC, Szatkowski DL, Brouwer RE, Westerman M, Leys MR, Sinnige HA, Haukås E, van der Hem KG, Durian MF, Mattijssen EV, van de Donk NW, Stevens-Kroef MJ, Sonneveld P, Waage A. Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. Blood. 2016 Mar 3;127(9):1109-16. doi: 10.1182/blood-2015-11-679415. PMID:26802176.
172	Slørdahl TS, Abdollahi P, Vandsemb EN, Rampa C, Misund K, Baranowska KA, Westhrin M, Waage A, Rø TB, Børset M. The phosphatase of regenerating liver-3 (PRL-3) is important for IL-6-mediated survival of myeloma cells. Oncotarget. Mar 27. doi: 10.18632/oncotarget.8422, 2016. PMID:27036022
173	Jurczyszyn A, Grzasko N, Gozzetti A, Czepiel J, Cerase A, Hungria V, Crusoe E, Silva Dias AL, Vij R, Fiala MA, Caers J, Rasche L, Nooka AK, Lonial S, Vesole DH, Philip S, Gangatharan S, Druzd-Sitek A, Walewski J, Corso A, Cocito F, Vekemans MC, Atilla E, Beksac M, Leleu X, Davila J, Badros A, Aneja E, Abildgaard N, Kastiritis E, Fantl D, Schutz N, Pika T, Butrym A, Olszewska-Szopa M, Usnarska-Zubkiewicz L, Usmani SZ, Nahi H, Chim CS, Shustik C, Madry K, Lentzsch S, Swiderska A, Helbig G, Guzicka-Kazimierzczak R, Lendvai N, Waage A, Andersen KT, Murakami H, Zweegman S, Castillo JJ. Central nervous system involvement

	by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. <i>Am J Hematol.</i> 2016 Jun;91(6):575-80. doi: 10.1002/ajh.24351. PMID:26955792.
174	Mitchell J, Li N, Broderick P, Henrion M, Lenive O, Weinhold N, Stephens O, Davies F, Morgan G, Chen B, Campo C, Inacio da Silva I Filho, Hemminki K, Ali M, Halvarsson B-M, Gullberg U, Johnsson E, Jöud M, Swaminathan B, Wihlborg A-K, Hansson M, Nilsson B, Kuiper R, Duin M, Broyl A, Sonneveld P, Thorleifsson G, Gudbjartsson D, Rafnar T, Thorsteinsdottir U, Stefansson K, Johnson D, Bertsch U, Hillengass J, Nickel J, Goldschmidt H, Einsele H, Gregory W, Hoffmann P, Jackson G, Kristinsson S, Lenhoff S, Mellqvist U-H, Nahi H, Nelander S, Nöthen M, Ross F, Turesson I, Vangsted A, Vogel U, Waage A, Walker B, Langer C, Kaiser M, Migliorini M, Försti A, Thomsen H, Houlston R, Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. <i>Nat Commun.</i> 2016;7:12050. PMID27363682
175	Starheim KK, Holien T, Misund K, Johansson I, Baranowska KA, Sponaas AM, Hella H, Buene G, Waage A, Sundan A, Bjørkøy G. Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells. <i>J Blood Cancer,</i> 2016 Jul 15;6(7):e446. PMID 27421095
176	Våtsveen TK, Sponaas AM, Tian E, Zhang Q, Misund K, Sundan A, Børset M, Waage A, Brede G. Erythropoietin (EPO)-receptor signaling induces cell death of primary myeloma cells in vitro. <i>J Hematol Oncol.</i> 2016 Aug 31;9(1):75. PMID 27581518
177	Våtsveen TK, Børset M, Dikic A, Tian E, Micci F, Lid AH, Meza-Zepeda LA, Coward E, Waage A, Sundan A, Kuehl WM, Holien T. VOLIN and KJON-Two novel hyperdiploid myeloma cell lines. <i>Genes Chromosomes Cancer.</i> 2016;55:890-901. PMID 27311012
178	Baranowska K, Misund K, Starheim KK, Holien T, Johansson I, Darvekar S, Buene G, Waage A, Bjørkøy G, Sundan A. Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells. <i>Oncotarget.</i> 2016;7:70845-56. PMID 27683126
179	Krogh AS, Waage A, Quist-Paulsen P. Congenital thrombotic thrombocytopenic purpura. <i>Tidsskr Nor Laegeforen.</i> 2016, 136:1452-7. PMID 27686205
180	Zatula A, Dikic A, Mulder C, Sharma A, Vågbø CB, Sousa MM, Waage A, Slupphaug G. Proteome alterations associated with transformation of multiple myeloma to secondary plasma cell leukemia. <i>Oncotarget.</i> 2017 ;8:19427-42. PMID 28038447
181	Rustad EH, Coward E, Skytøen ER, Misund K, Holien T, Standal T, Børset M, Beisvag V, Myklebost O, Meza-Zepeda LA, Dai HY, Sundan A, Waage A. Monitoring of multiple myeloma by quantification of recurrent mutations in serum. <i>Haematologica.</i> 2017 Apr 6. PMID:28385781